BMS' Bid For Opdivo In First-Line HCC Stymied

 
• By Joseph Haas

Top-line results from a Phase III study testing Opdivo versus Nexavar in first-line liver cancer fail to meet OS target. Bristol points to positive numerical trend, but the results are a setback in the indication.

Digital illustration of lung cancer cells in color background - Illustration
Opdivo is approved for second-line HCC therapy

More from Immuno-oncology

More from Anticancer